{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:46:07Z","timestamp":1790045167594,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40261-024-01386-8","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:49:16Z","timestamp":1724410156000},"page":"687-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-5251","authenticated-orcid":false,"given":"Gianni","family":"Ghetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Saverio","family":"Mennini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele Maria","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.nmd.2016.06.459","volume":"26","author":"JK Burns","year":"2016","unstructured":"Burns JK, Kothary R, Parks RJ. Opening the window: The case for carrier and perinatal screening for spinal muscular atrophy. Neuromuscul Disord. 2016;26:551\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2016.06.459.","journal-title":"Neuromuscul Disord"},{"key":"1386_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10897-015-9859-z","volume":"25","author":"A Carr\u00e9","year":"2016","unstructured":"Carr\u00e9 A, Empey C. Review of spinal muscular atrophy (SMA) for prenatal and pediatric genetic counselors. J Genet Couns. 2016;25:32\u201343. https:\/\/doi.org\/10.1007\/s10897-015-9859-z.","journal-title":"J Genet Couns"},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2174\/156652409789105516","volume":"9","author":"MA Farrar","year":"2009","unstructured":"Farrar MA, Johnston HM, Grattan-Smith P, Turner A, Kiernan MC. Spinal muscular atrophy: molecular mechanisms. Curr Mol Med. 2009;9:851\u201362. https:\/\/doi.org\/10.2174\/156652409789105516.","journal-title":"Curr Mol Med"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet. 2020;21:231\u201361. https:\/\/doi.org\/10.1146\/annurev-genom-102319-103602.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"1386_CR5","unstructured":"Istituto Superiore di Sanit\u00e0. Screening neonatale. 5 Jan 2022. Available at: https:\/\/www.iss.it\/web\/guest\/screening-neonatali. Accessed 1 Apr 2024."},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","volume":"31","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Vr\u0161\u010daj E, Servais L, Osredkar D, SMA NBS World Study Group. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord. 2021;31:574\u201382. https:\/\/doi.org\/10.1016\/j.nmd.2021.03.007.","journal-title":"Neuromuscul Disord"},{"key":"1386_CR7","unstructured":"European Alliance for Newborn Screening in SMA. Spinal muscular atrophy: screen at birth, save lives. Whitepaper Version 2. 25 Nov 2021. Available at: https:\/\/nbs-alliance-assets.gpm.digital\/Spinal_muscular_atrophy_Screen_at_birth_save_lives_Whitepaper_SMA_NBS_Alliance_v2_25_NOV_2021_aa4fca4159.pdf. Accessed 1 Apr 2024."},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","volume":"181","author":"M Pane","year":"2022","unstructured":"Pane M, Donati MA, Cutrona C, et al. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur J Pediatr. 2022;181:2821\u20139. https:\/\/doi.org\/10.1007\/s00431-022-04470-3.","journal-title":"Eur J Pediatr"},{"key":"1386_CR9","unstructured":"European Medicines Agency. Spinraza nusinersen. 12 Oct 2023. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spinraza. Accessed 1 Apr 2024."},{"key":"1386_CR10","unstructured":"European Medicines Agency. Zolgensma onasemnogene abeparvovec. 26 Mar 2024. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma. Accessed 1 Apr 2024."},{"key":"1386_CR11","unstructured":"European Medicines Agency. Evrysdi risdiplam. 26 Mar 2024. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evrysdi. Accessed 1 Apr 2024."},{"issue":"10","key":"1386_CR12","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","volume":"25","author":"R Velikanova","year":"2022","unstructured":"Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Cost-effectiveness of newborn screening for spinal muscular atrophy in The Netherlands. Value Health. 2022;25(10):1696\u2013704. https:\/\/doi.org\/10.1016\/j.jval.2022.06.010.","journal-title":"Value Health."},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","volume":"190","author":"YH Chien","year":"2017","unstructured":"Chien YH, Chiang SC, Weng WC, et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr. 2017;190:124-9.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2017.06.042.","journal-title":"J Pediatr"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijns5020021","volume":"5","author":"A Strunk","year":"2019","unstructured":"Strunk A, Abbes A, Stuitje AR, et al. Validation of a fast, robust, inexpensive, two-tiered neonatal screening test algorithm on dried blood spots for spinal muscular atrophy. Int J Neonatal Screen. 2019;5:21. https:\/\/doi.org\/10.3390\/ijns5020021.","journal-title":"Int J Neonatal Screen."},{"issue":"7","key":"1386_CR15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes14071377","volume":"14","author":"K Aragon-Gawinska","year":"2023","unstructured":"Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L. Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review. Genes (Basel). 2023;14(7):1377. https:\/\/doi.org\/10.3390\/genes14071377.","journal-title":"Genes (Basel)."},{"key":"1386_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/009286150103500122","volume":"35","author":"S Capri","year":"2001","unstructured":"Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Inf J. 2001;35:189\u2013201. https:\/\/doi.org\/10.1177\/009286150103500122.","journal-title":"Drug Inf J"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","volume":"12","author":"C Lally","year":"2017","unstructured":"Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States. Orphanet J Rare Dis. 2017;12:175. https:\/\/doi.org\/10.1186\/s13023-017-0724-z.","journal-title":"Orphanet J Rare Dis"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","volume":"125","author":"L Al\u00edas","year":"2009","unstructured":"Al\u00edas L, Bernal S, Fuentes-Prior P, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125:29\u201339. https:\/\/doi.org\/10.1007\/s00439-008-0598-1.","journal-title":"Hum Genet"},{"issue":"1","key":"1386_CR19","doi-asserted-by":"publisher","first-page":"19922","DOI":"10.1038\/s41598-021-99496-2","volume":"11","author":"F Boemer","year":"2021","unstructured":"Boemer F, Caberg JH, Beckers P, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep. 2021;11(1):19922. https:\/\/doi.org\/10.1038\/s41598-021-99496-2.","journal-title":"Sci Rep"},{"issue":"3","key":"1386_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003.","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"1386_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"issue":"2","key":"1386_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54(2):179\u201385. https:\/\/doi.org\/10.1002\/ppul.24203.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"1386_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1386_CR24","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(21)00251-9.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1386_CR25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01866-4.","journal-title":"Nat Med"},{"issue":"7","key":"1386_CR26","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01867-3.","journal-title":"Nat Med"},{"issue":"15 Suppl","key":"1386_CR27","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1212\/WNL.94.15_supplement.1640","volume":"94","author":"D Castro","year":"2020","unstructured":"Castro D, Finkel RS, Farrar MA, et al. Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study (1640). Neurology. 2020;94(15 Suppl):1640.","journal-title":"Neurology"},{"key":"1386_CR28","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92:e2492\u2013506. https:\/\/doi.org\/10.1212\/WNL.0000000000007527.","journal-title":"Neurology"},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","journal-title":"Neuromuscul Disord"},{"issue":"Suppl 1","key":"1386_CR30","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/j.nmd.2020.08.258","volume":"30","author":"G Baranello","year":"2020","unstructured":"Baranello G, Bloespflug-Tanguy O, Darras B, et al. P.259 FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). Neuromuscul Disord. 2020;30(Suppl 1):S122. https:\/\/doi.org\/10.1016\/j.nmd.2020.08.258.","journal-title":"Neuromuscul Disord"},{"issue":"15 Suppl","key":"1386_CR31","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.94.15_supplement.1302","volume":"94","author":"L Servais","year":"2020","unstructured":"Servais L, Baranello G, Masson R, et al. FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA) (1302). Neurology. 2020;94(15 Suppl):1302.","journal-title":"Neurology"},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2009965.","journal-title":"N Engl J Med"},{"key":"1386_CR33","unstructured":"Servais L, Al-Muhaizea M, Farrar MA, et al. RAINBOWFISH: a study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA). In: Presented at the World Muscle Society 2021 Virtual Congress, 20\u201324 September 2021."},{"issue":"5","key":"1386_CR34","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314. https:\/\/doi.org\/10.1542\/peds.2012-2278.","journal-title":"Pediatrics"},{"key":"1386_CR35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883\u201391. https:\/\/doi.org\/10.1002\/ana.25101.","journal-title":"Ann Neurol"},{"key":"1386_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0022-510x(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146:67\u201372. https:\/\/doi.org\/10.1016\/s0022-510x(96)00284-5.","journal-title":"J Neurol Sci"},{"key":"1386_CR37","unstructured":"ISTAT. Tavole di mortalit\u00e0 della popolazione. Anno 2020.19 Dec 2022. Available at: https:\/\/demo.istat.it\/. Accessed 1 Apr 2024."},{"key":"1386_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","volume":"32","author":"V Diaby","year":"2014","unstructured":"Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32:101\u20138. https:\/\/doi.org\/10.1007\/s40273-013-0123-9.","journal-title":"Pharmacoeconomics"},{"key":"1386_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"AH Briggs","year":"2006","unstructured":"Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"key":"1386_CR40","unstructured":"Institute for Clinical and Economic Review. Spinraza and Zolgensma for spinal muscular atrophy: effectiveness and value. 2019. Available at: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_110220.pdf. Accessed 1 Apr 2024."},{"key":"1386_CR41","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy. Highly specialised technologies guidance. HST15. 7 Jul 2021. Available at: https:\/\/www.nice.org.uk\/guidance\/hst15. Accessed 1 Apr 2024."},{"key":"1386_CR42","doi-asserted-by":"publisher","unstructured":"Scalone L, Cortesi P, Ciampichini R, Cesana G, Mantovani L. Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol Biostat Public Health. 2015;12:e11457-1\u201315. https:\/\/doi.org\/10.2427\/11457","DOI":"10.2427\/11457"},{"key":"1386_CR43","unstructured":"Gazzetta Ufficiale. Regime di rimborsabilit\u00e0 e prezzo del medicinale per uso umano Zolgensma. 13 Mar 2021. Available at: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2021\/03\/13\/21A01554\/sg. Accessed 1 Apr 2024."},{"key":"1386_CR44","unstructured":"Gazzetta Ufficiale. Rinegoziazione del medicinale per uso umano Spinraza ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. 20 Feb 2021. Available at: https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2021-02-20&atto.codiceRedazionale=21A01038&elenco30giorni=false. Accessed 1 Apr 2024."},{"key":"1386_CR45","unstructured":"Gazzetta Ufficiale. Riclassificazione del medicinale per uso umano Evrysdi, ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. 7 Feb 2022. Available at: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2022\/02\/07\/22A00781\/sg. Accessed 1 Apr 2024."},{"key":"1386_CR46","unstructured":"World Health Organization. Tools and toolkits. 2022. Available at: https:\/\/www.who.int\/tools. Accessed 1 Apr 2024."},{"key":"1386_CR47","unstructured":"Gazzetta Ufficiale. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. 2012. Available at: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2013\/01\/28\/13A00528\/sg. Accessed 1 Apr 2024."},{"key":"1386_CR48","unstructured":"Regione Lombardia. Deliberazione n\u00b0 IX \/ 2946 del 25\/01\/2012. Available at: https:\/\/web.archive.org\/web\/20220802051132\/https:\/\/www.assolombarda.it\/fs\/20122115055_141.pdf. Accessed 1 Apr 2024."},{"key":"1386_CR49","doi-asserted-by":"crossref","unstructured":"Belisari A, D\u2019Angiolella LS, Mantovani LG, Sansone V, Vita G, Pane M. Healthcare costs of patients with spinal muscular atrophy. Presented at ISPOR Europe 2018. Barcelona, Spain; 10\u201314 November 2018.","DOI":"10.1016\/j.jval.2018.09.2008"},{"issue":"1","key":"1386_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40273-022-01215-w","volume":"41","author":"P Russo","year":"2023","unstructured":"Russo P, Zanuzzi M, Carletto A, Sammarco A, Romano F, Manca A. Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023;41(1):107\u201317. https:\/\/doi.org\/10.1007\/s40273-022-01215-w.","journal-title":"Pharmacoeconomics"},{"key":"1386_CR51","unstructured":"ISTAT. Bilancio demografico. Anno 2020. Available at: https:\/\/demo.istat.it\/. Accessed 1 Apr 2024."},{"key":"1386_CR52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.31128\/AJGP-03-21-5924","volume":"51","author":"JE Davidson","year":"2022","unstructured":"Davidson JE, Farrar MA. The changing therapeutic landscape of spinal muscular atrophy. Aust J Gen Pract. 2022;51:38\u201342. https:\/\/doi.org\/10.31128\/AJGP-03-21-5924.","journal-title":"Aust J Gen Pract."},{"issue":"3","key":"1386_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","volume":"7","author":"DS Kariyawasam","year":"2023","unstructured":"Kariyawasam DS, D\u2019Silva AM, Sampaio H, et al. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child Adolesc Health. 2023;7(3):159\u201370. https:\/\/doi.org\/10.1016\/S2352-4642(22)00342-X.","journal-title":"Lancet Child Adolesc Health."},{"key":"1386_CR54","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.nmd.2021.08.009","volume":"31","author":"E Mercuri","year":"2021","unstructured":"Mercuri E. Spinal muscular atrophy: from rags to riches. Neuromuscul Disord. 2021;31:998\u20131003. https:\/\/doi.org\/10.1016\/j.nmd.2021.08.009.","journal-title":"Neuromuscul Disord"},{"key":"1386_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","volume":"5","author":"J Glascock","year":"2018","unstructured":"Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5:145\u201358. https:\/\/doi.org\/10.3233\/JND-180304.","journal-title":"J Neuromuscul Dis."},{"key":"1386_CR56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","volume":"7","author":"J Glascock","year":"2020","unstructured":"Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7:97\u2013100. https:\/\/doi.org\/10.3233\/JND-190468.","journal-title":"J Neuromuscul Dis."},{"key":"1386_CR57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3233\/JND-221510","volume":"9","author":"A Blaschek","year":"2022","unstructured":"Blaschek A, K\u00f6lbel H, Schwartz O, et al. Newborn screening for SMA - can a wait-and-see strategy be responsibly justified in patients with four SMN2 copies? J Neuromuscul Dis. 2022;9:597\u2013605. https:\/\/doi.org\/10.3233\/JND-221510.","journal-title":"J Neuromuscul Dis."},{"key":"1386_CR58","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1017\/cjn.2020.229","volume":"48","author":"HJ McMillan","year":"2021","unstructured":"McMillan HJ, Kernohan KD, Yeh E, et al. Newborn screening for spinal muscular atrophy: Ontario testing and follow-up recommendations. Can J Neurol Sci. 2021;48:504\u201311. https:\/\/doi.org\/10.1017\/cjn.2020.229.","journal-title":"Can J Neurol Sci"},{"key":"1386_CR59","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","volume":"12","author":"D Weidlich","year":"2023","unstructured":"Weidlich D, Servais L, Kausar I, Howells R, Bischof M. Cost-effectiveness of newborn screening for spinal muscular atrophy in England. Neurol Ther. 2023;12:1205\u201320. https:\/\/doi.org\/10.1007\/s40120-023-00489-2.","journal-title":"Neurol Ther."},{"key":"1386_CR60","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"ST Shih","year":"2021","unstructured":"Shih ST, Farrar MA, Wiley V, Chambers G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021;92:1296\u2013304. https:\/\/doi.org\/10.1136\/jnnp-2021-326344.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1386_CR61","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali A, Rothwell E, Botkin JR, Anderson RA, Butterfield RJ, Nelson RE. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020;227:274-280.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2020.07.033.","journal-title":"J Pediatr"},{"key":"1386_CR62","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","volume":"37","author":"M Bischof","year":"2021","unstructured":"Bischof M, Lorenzi M, Lee J, Druyts E, Balijepalli C, Dabbous O. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin. 2021;37:1719\u201330. https:\/\/doi.org\/10.1080\/03007995.2021.1947216.","journal-title":"Curr Med Res Opin"},{"key":"1386_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1586\/14737159.4.1.15","volume":"4","author":"S Ogino","year":"2004","unstructured":"Ogino S, Wilson RB. Spinal muscular atrophy: molecular genetics and diagnostics. Expert Rev Mol Diagn. 2004;4:15\u201329. https:\/\/doi.org\/10.1586\/14737159.4.1.15.","journal-title":"Expert Rev Mol Diagn"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01386-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T20:06:10Z","timestamp":1728158770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01386-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01386-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"4 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis and manuscript were sponsored and funded by Novartis Gene Therapies, Inc. Novartis Gene Therapies, Inc., employees were involved in the study design and data analysis, and in the writing of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gianni Ghetti is an employee of AdRes HEOR s.r.l., which has received project funding from Novartis Gene Therapies, Inc. Andrea Marcellusi received support from Novartis for this work. Matthias Bischof is an employee of Novartis Gene Therapies GmbH, Rotkreuz, Switzerland, and owns Novartis stock or other equities. Gabriele Maria Pistillo is an employee of Novartis Gene Therapies, Milan, Italy, and owns Novartis stock or other equities. Francesco Saverio Mennini and Marika Pane report no conflicts of interest that may be relevant to the contents of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data generated or analyzed during this study are included in this published article and are available from the authors under reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"As no new studies with human participants were included in this analysis, Institutional Review Board approval was not required, patient consent to participate was not necessary, and the Declaration of Helsinki 1964 does not apply.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors contributed to the conception and design of the research. GG adapted the model to the Italian setting and conducted the analyses. GG, MB, and GMP collaborated on the writing and development of the final draft of this manuscript. All authors participated in the interpretation of study results and in the critical revision and approval of the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}